Singapore markets open in 8 hours 31 minutes

Novartis AG (NVSEF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
84.85+0.84 (+1.00%)
As of 11:28AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close84.01
Bid0.00 x 0
Ask0.00 x 0
Day's range82.10 - 84.91
52-week range78.78 - 95.00
Avg. volume23,911
Market cap194.492B
Beta (5Y monthly)0.48
PE ratio (TTM)7.91
EPS (TTM)10.73
Earnings dateN/A
Forward dividend & yield3.35 (4.24%)
Ex-dividend date08 Mar 2022
1y target estN/A
  • Reuters

    Novartis to cut up to 8,000 jobs globally

    ZURICH (Reuters) -Novartis said on Tuesday a previously announced restructuring programme could lead to 8,000 jobs being cut, including up to 1,400 in Switzerland, confirming a report by Swiss newspaper TagesAnzeiger. Novartis said in an emailed statement it had made good progress in implementing its new organisational structure that involved integrating its pharmaceuticals and oncology business units and would lead to eliminating roles across the organisation. "This restructuring could potentially impact 1,400 positions based in Switzerland, out of around 8,000 positions impacted globally," the company said, adding it had currently 108,000 employees globally, including 11,600 in Switzerland.

  • Zacks

    Q2 Earnings Season Preview and Featured Analyst Reports for J&J, AMD & Union Pacific

    Today's Research Daily features preview of the Q2 earnings season and new research reports for J&J (JNJ), AMD (AMD), and Union Pacific (UNP).

  • Zacks

    Novartis (NVS) Gets Positive CHMP Opinion for Scemblix in CML

    The CHMP recommends approval of Novartis' (NVS) Scemblix for treating adult patients with chronic myeloid leukemia. EU also approves label expansion of Cosentyx.